AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
fenbendazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anthelminthics, tiabendazole derivatives | 4536 | 43210-67-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antinematodal benzimidazole used in veterinary medicine.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.946 | High | 0.84 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.769 | High | 0.84 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 72.111 | 10^-6 cm/s | High | 0.84 |
| dh-clint | Dog hepatocyte intrinsic clearance | 15.031 | uL/min/10^6 cells | High | 0.84 |
| dppb | Dog plasma protein binding (% unbound) | 1.010 | % | High | 0.84 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 2.450 | % | High | 0.84 |
| herg | hERG pIC50 | 4.696 | pIC50 | High | 0.84 |
| hh-clint | Human hepatocyte intrinsic clearance | 12.972 | uL/min/10^6 cells | High | 0.84 |
| hlm-clint | Human liver microsomal intrinsic clearance | 34.041 | uL/min/mg protein | High | 0.84 |
| hppb | Human plasma protein binding (% unbound) | 0.630 | % | High | 0.84 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SGK1,SIK2,SIK3,STK33,TEK,TTK | 45 | |||
| kinase-selectivity-class | ACVR2B,AURKA,CDK9,CSF1R,DDR1,EGFR,ERBB2,FLT3,GRK2,JAK1,MAP2K6,MAP3K1,MAP3K21,MAPK7,MARK4,PDK4,SIK2,SIK3,STK33 | 19 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.346 | High | 0.84 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 74.302 | High | 0.84 | |
| mppb | Mouse plasma protein binding (% unbound) | 1 | High | 0.84 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.250 | High | 0.84 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 2.330 | % | High | 0.84 |
| rh-clint | Rat hepatocyte intrinsic clearance | 28.379 | uL/min/10^6 cells | High | 0.84 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 13.870 | % | High | 0.84 |
| rppb | Rat plasma protein binding (% unbound) | 0.530 | % | High | 0.84 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1.146 | uM | High | 0.84 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P02CA06 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000969 | Antinematodal Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| CHEBI has role | CHEBI:35443 | anthelminthic drug |
| CHEBI has role | CHEBI:35444 | antinematodal drug |
Related Drugs by ATC class:
P02CA Benzimidazole derivatives 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Removal and control of lungworm, Dictyocaulus viviparus | Indication |
| Cattle | Removal and control of stomach worm (adults) | Indication |
| Cattle | Removal and control of brown stomach wormd, Ostertagia ostertagi | Indication |
| Cattle | Removal and control of stomach worms (adults and 4th-stage larvae) | Indication |
| Cattle | Removal and control of barberpole worms, H placei | Indication |
| Cattle | Removal and control of small stomach worms, Trichostrongylus axei | Indication |
| Cattle | Removal and control of intestinal worms (adults and 4th-stage larvae) | Indication |
| Cattle | Removal and control of hookworm, Bunostomum phlebotomum | Indication |
| Cattle | Removal and control of threadnecked intestinal worms, Nematodirus helvetianus | Indication |
| Cattle | Removal and control of small intestinal worms, Cooperia punctata | Indication |
| Cattle | Removal and control of bankrupt worms, Trichostrongylus colubriformis | Indication |
| Cattle | Removal and control of nodular worm, Oesophagostomum radiatum | Indication |
| Cattle | Removal and control of barberpole worms, H placei | Indication |
| Cattle | Removal and control of small intestinal worms, C oncophora | Indication |
| Goats | Removal and control of stomach worms, Haemonchus contortus (adults) | Indication |
| Goats | Removal and control of stomach worms, Teladorsagia circumcincta | Indication |
| Horses | Control of large strongyles, Strongylus edentatus | Indication |
| Horses | Control of small strongyles, Cyathostomum species | Indication |
| Horses | Control of pinworms, Oxyuris equi | Indication |
| Horses | Control of ascarids (Parascaris equorum) | Indication |
| Horses | Control of large strongyles, S equinus | Indication |
| Horses | Control of large strongyles, S vulgaris | Indication |
| Horses | Control of small strongyles, Cylicocyclus species | Indication |
| Horses | Control of small strongyles, Cylicostephanus species | Indication |
| Horses | Control of small strongyles, Triodontophorus species | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Panacur Suspension 10% | Intervet Inc. | 1 |
| Panacur Granules 22.2% | Intervet Inc. | 1 |
| panacur, safe-guard | Intervet Inc. | 1 |
| Panacur C (OTC), Safe-Guard Canine (OTC), Panacur Granules 22.2% (Rx) | Intervet Inc. | 1 |
| Safe-Guard , Panacur | Intervet Inc. | 1 |
| Safe-Guard | Intervet Inc. | 1 |
| Panacur 10% Paste, Safe-Guard | Intervet Inc. | 1 |
| Safe-Guard Type A Medicated Article | Intervet Inc. | 1 |
| Safe-Guard | Intervet Inc. | 1 |
| SAFE-GUARD plus LINCOMIX | Intervet Inc. | 2 |
| BMD / Safe-Guard | Zoetis Inc. | 2 |
| Panacur Plus | Intervet Inc. | 3 |
| Safe-Guard AquaSol | Intervet Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.61 | acidic |
| pKa2 | 13.2 | acidic |
| pKa3 | 3.71 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mitogen-activated protein kinase 14 | Kinase | IC50 | 5.50 | DRUG MATRIX | |||||
| Beta-lactamase 1 | Enzyme | IC50 | 5.22 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| D04140 | KEGG_DRUG |
| N0000166935 | NUI |
| CHEBI:77092 | CHEBI |
| CHEMBL37161 | ChEMBL_ID |
| 3395 | INN_ID |
| DB11410 | DRUGBANK_ID |
| 621BVT9M36 | UNII |
| 4325 | RXNORM |
| NOCODE | MMSL |
| 013514 | NDDF |
| 96134008 | SNOMEDCT_US |
| C0015821 | UMLSCUI |
| D005273 | MESH_DESCRIPTOR_UI |
| 3334 | PUBCHEM_CID |
| 621BVT9M36 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Fenbendazole 222 MG | HUMAN OTC DRUG LABEL | 1 | 85130-100 | CAPSULE | 299.35 mg | ORAL | unapproved drug other | 7 sections |
| FENBENDAZOLE Oral Dewormer | HUMAN OTC DRUG LABEL | 1 | 87276-263 | PASTE | 100 mg | ORAL | OTC Monograph Drug | 7 sections |
| PREPAKU FENBENDAZOLE Canine Dewormer | HUMAN OTC DRUG LABEL | 1 | 87276-264 | GRANULE | 222 mg | ORAL | OTC Monograph Drug | 7 sections |